In early October 2025, TripleTree attended SCRS 2025 alongside the industry’s most prominent thought-leaders, innovators, and clinical research professionals. The dynamic dialogue revolved around a predominant theme – cautious optimism – which TripleTree feels perfectly encapsulates the current state of the clinical trial ecosystem. As an active M&A advisor in the clinical trial outsourcing landscape, TripleTree is excited to share key observations and collective learnings from the SCRS summit, including recent deal activity, key themes shaping the industry, and insights into future clinical site M&A activity.
Read the full article: Navigating the Crosscurrents: Insights from SCRS 2025 and the Evolving Clinical Trial Landscape //
Source: https://www.triple-tree.com/insights/navigating-the-crosscurrents-insights-from-scrs-2025-and-the-evolving-clinical-trial-landscape/